Valuation: CervoMed Inc.

Market Cap 24.19M 21.67M 19.93M 18.06M 33.75M 2.3B 34.38M 238M 95.4M 1.21B 90.78M 88.85M 3.81B P/E 2026 *
-0.74x
P/E 2027 * -1.08x
Enterprise Value -135M -121M -111M -101M -188M -12.79B -191M -1.32B -531M -6.73B -506M -495M -21.22B EV / Sales 2026 *
-1,010x
EV / Sales 2027 * -113x
Free-Float
73.57%
Yield 2026 *
-
Yield 2027 * -
1 day-8.57%
1 week-30.74%
Current month-46.13%
1 month-46.13%
3 months-36.51%
6 months-56.64%
Current year-79.75%
1 week 1.6
Extreme 1.6
2.3
1 month 1.6
Extreme 1.6
3.44
Current year 1.6
Extreme 1.6
8.22
1 year 1.6
Extreme 1.6
10
3 years 1.6
Extreme 1.6
26.38
5 years 1.6
Extreme 1.6
26.38
10 years 1.6
Extreme 1.6
26.38
Manager TitleAgeSince
Chief Executive Officer 64 2023-08-15
Director of Finance/CFO 42 2024-02-29
Chief Tech/Sci/R&D Officer 49 2025-05-31
Director TitleAgeSince
Director/Board Member 64 2023-08-15
Chairman 64 2018-03-31
Director/Board Member 68 2020-08-31
Date Insider Type Main position Quantity % Market Cap. Importance
2/11/26 Free

Executive/Senior Manager

30,000 0.3242%
2/11/26 Free

Chief Financial Officer

30,000 0.3242%
2/11/26 Free

General Counsel

30,000 0.3242%
Change 5-day change 1-year change 3-year change Capi.($)
-8.57%-30.74%-77.50%-81.37% 26.46M
-0.62%-1.87%+46.31%+56.99% 64.38B
+0.35%+3.20%+14.92%+84.55% 56.16B
+0.53%+1.96%+15.37%+106.81% 54.16B
-2.81%-4.31%+23.50%+50.90% 45.33B
-0.33%-1.93%+20.15%+98.45% 42.25B
+0.55%+2.31%+224.97%+942.56% 40.78B
+3.27%+47.96%+112.67%+96.48% 33.8B
+1.22%-1.44%+14.89%+47.15% 32.25B
-1.29%-2.88%+21.60%-11.92% 23.57B
Average -0.77%+1.09%+41.69%+139.06% 39.27B
Weighted average by Cap. +0.02%+3.54%+52.30%+161.97%

Financials

2026 *2027 *
Net sales 133K 119K 110K 99.52K 186K 12.66M 190K 1.31M 526K 6.66M 500K 490K 21M 833K 746K 687K 622K 1.16M 79.13M 1.18M 8.19M 3.29M 41.62M 3.13M 3.06M 131M
Net income -29.16M -26.12M -24.02M -21.77M -40.69M -2.77B -41.45M -286M -115M -1.46B -109M -107M -4.59B -43.42M -38.89M -35.77M -32.41M -60.58M -4.12B -61.72M -427M -171M -2.17B -163M -159M -6.84B
Net Debt -159M -142M -131M -119M -222M -15.09B -226M -1.56B -627M -7.94B -596M -584M -25.03B -118M -106M -97.46M -88.3M -165M -11.23B -168M -1.16B -467M -5.91B -444M -435M -18.63B
Projected Income Statement - Annual - CervoMed Inc.
Logo CervoMed Inc.
CervoMed Inc. is a clinical-stage company focused on developing treatments for age-related neurologic disorders. The Company is developing neflamapimod, an investigational, orally administered small molecule brain penetrant that inhibits p38 mitogen-activated protein kinase alpha. Neflamapimod has the potential to treat synaptic dysfunction, the reversible aspect of the underlying neurodegenerative processes that cause disease in Lewy bodies (DLB) and certain other neurological disorders. It focuses on reducing the impact of inflammation in the brain, or neuroinflammation, which is a key factor in the manifestation of degenerative diseases of the brain, including DLB. Neflamapimod is being evaluated in the Company's ongoing RewinD-LB Trial, a Phase 2b trial in patients with DLB.
Employees
15
Date Price Change Volume
26-10-30 US$1.600 -8.57% 583,899
26-10-29 US$1.750 -20.81% 1,168,877
26-10-28 US$2.210 -0.45% 201,600
26-10-27 US$2.220 -0.89% 150,558
26-10-26 US$2.240 -3.03% 103,966
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
MarketScreener Ratings - CervoMed Inc.
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
6
Last Close Price
1.600USD
Average target price
15.00USD
Spread / Average Target
+837.50%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - CervoMed Inc.
  1. Stock Market
  2. Stocks
  3. CRVO Stock